BPG is committed to discovery and dissemination of knowledge
Retrospective Cohort Study
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Hepatol. Sep 27, 2026; 18(9): 123924
Published online Sep 27, 2026. doi: 10.4254/wjh.123924
Radiologic partial response poorly predicts pathologic complete response in hepatocellular carcinoma after conversion therapy
Chi Xu, Qiong-Yu Liang, Jia-Peng Sun, Kang Zhou, Jie Pan, Hai-Tao Zhao
Chi Xu, Qiong-Yu Liang, Department of Interventional Treatment, Beijing No. 6 Hospital, Beijing 100007, China
Jia-Peng Sun, Kang Zhou, Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China
Jie Pan, Department of Radiology, Peking Union Medical College Hospital, Beijing 100730, China
Hai-Tao Zhao, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
Co-first authors: Chi Xu and Qiong-Yu Liang.
Co-corresponding authors: Jie Pan and Hai-Tao Zhao.
Author contributions: Xu C, Liang QY, Zhou K, Pan J, and Zhao HT designed the research study; Xu C and Liang QY contributed equally to this article and are the co-first authors of this manuscript; Xu C, Liang QY, and Sun JP performed the research and acquired the data; Zhou K, Pan J, and Zhao HT contributed to the multidisciplinary evaluation of the patients; Liang QY and Sun JP analysed the data; Xu C, Liang QY, Sun JP, and Zhou K wrote and critically revised the manuscript; and all authors have read and approved the final manuscript. Pan J and Zhao HT are co-corresponding authors. They contributed equally as they designed the study, contributed to the multidisciplinary evaluation of patients and supervised the whole research.
AI contribution statement: The authors take full responsibility and accountability for all content of this manuscript, including any portions for which AI tools were used as assistive technologies. All AI-assisted outputs were carefully reviewed, validated, and approved by the authors. AI tools were not used to generate original scientific data, perform independent scientific analyses, or draw scientific conclusions.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board and the Ethics Committee of Peking Union Medical College Hospital (approval No. I-25PJ3360).
Informed consent statement: All study participants, or their legal guardians, provided written informed consent before study enrolment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: Participants provided informed consent for data sharing. The dataset is available from the corresponding author at markpan6885@163.com.
Corresponding author: Jie Pan, MD, PhD, Department of Radiology, Peking Union Medical College Hospital, No. 1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing 100730, China. markpan6885@163.com
Received: June 2, 2026
Revised: July 17, 2026
Accepted: August 28, 2026
Published online: September 27, 2026
Processing time: 108 Days and 4.9 Hours
Abstract
BACKGROUND

Conversion therapy has increased the proportion of patients with initially unresectable hepatocellular carcinoma (HCC) who become eligible for surgical resection. Radiologic response criteria, including Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and modified RECIST (mRECIST), are widely used to evaluate treatment efficacy. However, their ability to predict pathologic complete response (pCR) remains uncertain.

AIM

To evaluate RECIST 1.1 and mRECIST for predicting pathological complete response and radiologic-pathologic discordance after HCC conversion therapy surgery.

METHODS

We retrospectively analysed 66 patients with initially unresectable HCC underwent curative-intent resection after conversion therapy between January 2019 and February 2024. Radiologic response was evaluated using RECIST 1.1 and mRECIST based on the last preoperative contrast-enhanced computed tomography or magnetic resonance imaging scan. pCR was defined as the absence of viable tumour cells in the resected specimens. The predictive performance of radiologic partial response (PR) for pCR was evaluated using sensitivity, specificity, positive predictive value (PPV), negative predictive value, and Cohen’s kappa.

RESULTS

According to mRECIST, 55 patients were classified as having PR and 11 as having stable disease (SD), whereas RECIST 1.1 categorised 37 patients as having PR and 29 as having SD. Overall, 20 patients (30.3%) achieved pCR. Under the mRECIST criteria, all patients with pCR were classified as having PR, yielding a sensitivity of 100% but a low specificity of 23.9% and a PPV of 36.4%. For RECIST 1.1, the sensitivity and specificity were 60.0% and 45.7%, respectively. Agreement between radiologic PR and pCR was poor for both criteria (Cohen’s κ = 0.16 for mRECIST and 0.046 for RECIST 1.1). These findings indicate substantial discordance between radiologic PR and pathological response.

CONCLUSION

Radiologic PR does not reliably predict pCR after HCC conversion therapy. Imaging alone should not guide surgical timing; integrating clinical and biological markers may improve preoperative response assessment.

Keywords: Hepatocellular carcinoma; Conversion therapy; Pathologic complete response; Radiologic-pathologic correlation; Surgical resection

Core Tip: Radiologic response is widely used to assess treatment efficacy in hepatocellular carcinoma after conversion therapy, yet its correlation with pathological response remains uncertain. In this study, radiologic partial response assessed by both Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 and modified RECIST showed poor concordance with pathologic complete response (pCR). Although all patients achieving pCR were classified as responders by modified RECIST, most radiologic responders still had residual viable tumor. These findings underscore the limitations of imaging-based response assessment and support the integration of additional biomarkers to improve preoperative evaluation and treatment planning.

Write to the Help Desk